Perspective
Coxibs and Cardiovascular Disease
N Engl J Med 2004; 351:1709-1711October 21, 2004
- Article
The coxibs are a subclass of nonsteroidal antiinflammatory drugs (NSAIDs) designed to inhibit selectively cyclooxygenase-2 (COX-2).1 Their development was based on the hypothesis that COX-2 was the source of prostaglandins E2 and I2, which mediate inflammation, and that cyclooxygenase-1 (COX-1) was the source of the same prostaglandins in gastric epithelium, where they afford cytoprotection. Three coxibs — celecoxib, rofecoxib, and valdecoxib — have been approved for use by the Food and Drug Administration (FDA); a fourth, etoricoxib, has been approved by the European regulatory authority, and it and a fifth, lumiracoxib, are currently under consideration for FDA approval.
Coxibs have been aggressively marketed directly to consumers in the United States and have rapidly dominated the prescription-drug market for NSAIDs, accounting for worldwide sales of roughly $10 billion. Rofecoxib has now been withdrawn from the market by Merck, following the premature cessation, by the data and safety monitoring board, of the Adenomatous Polyp Prevention on Vioxx (APPROVe) study, which was designed to determine the drug's effect on benign sporadic colonic adenomas. This action was taken because of a significant increase by a factor of 3.9 in the incidence of serious thromboembolic adverse events in the group receiving 25 mg of rofecoxib per day as compared with the placebo group. Blood pressure was elevated in patients in the rofecoxib group early in the course of the study, but the incidence of myocardial infarction and thrombotic stroke in the two groups began to diverge progressively after a year or more of treatment.
Coincident with the approval of rofecoxib and celecoxib in 1999, my colleagues and I reported that both drugs suppressed the formation of prostaglandin I2 in healthy volunteers.2 Prostaglandin I2 had previously been shown to be the predominant cyclooxygenase product in endothelium, inhibiting platelet aggregation, causing vasodilatation, and preventing the proliferation of vascular smooth-muscle cells in vitro. However, it was assumed that prostaglandin I2 was derived mainly from COX-1, the only cyclooxygenase species expressed constitutively in endothelial cells. This assumption later proved incorrect, since studies in mice and humans showed that COX-2 was the dominant source. The individual cardiovascular effects of prostaglandin I2 in vitro contrast with those of thromboxane A2, the major COX-1 product of platelets, which causes platelet aggregation, vasoconstriction, and vascular proliferation.
Whereas aspirin and traditional NSAIDs inhibit both thromboxane A2 and prostaglandin I2, the coxibs leave thromboxane A2 generation unaffected, reflecting the absence of COX-2 in platelets. Increasing laminar shear stress in vitro increases the expression of the gene for COX-2, leading our group to suggest that COX-2 might be hemodynamically induced in endothelial cells in vivo. If so, suppression of the COX-2–dependent formation of prostaglandin I2 by the coxibs might predispose patients to myocardial infarction or thrombotic stroke.
Thus, a single mechanism, depression of prostaglandin I2 formation, might be expected to elevate blood pressure, accelerate atherogenesis, and predispose patients receiving coxibs to an exaggerated thrombotic response to the rupture of an atherosclerotic plaque. The higher a patient's intrinsic risk of cardiovascular disease, the more likely it would be that such a hazard would manifest itself rapidly in the form of a clinical event.
How does previous clinical experience accord with this mechanistic hypothesis? Celecoxib, rofecoxib, and valdecoxib were approved by the FDA on the basis of trials that typically lasted three to six months and in which the end point was a clinical surrogate — endoscopically visualized gastric ulceration. After the drugs were approved, the results of two studies of gastrointestinal outcomes were reported: the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial and the Celecoxib Long Term Arthritis Safety Study (CLASS) trial. In the VIGOR trial, the rate of serious gastrointestinal events among those receiving rofecoxib was half that among those receiving a traditional NSAID, naproxen — 2 percent, as compared with 4 percent. However, a significant increase by a factor of five in the incidence of myocardial infarction was observed. Although this increase was a source of concern, it was argued that the small number of events reflected the play of chance or that naproxen was actually cardioprotective. However, epidemiologic studies of possible cardioprotection afforded by naproxen have proved inconclusive.2
In the CLASS trial, celecoxib was compared with ibuprofen or diclofenac.1,2 In the original report, celecoxib appeared to have a more favorable gastrointestinal-side-effect profile, and no increase in cardiovascular risk was revealed. However, this report contained only half the data (from only six months of a one-year study): when the full data set became available, it was clear that celecoxib did not differ from the traditional NSAIDs in its effect on the predefined gastrointestinal end points.2 Indeed, the most powerful evidence supporting claims of celecoxib's superiority over traditional NSAIDs in terms of gastrointestinal effects rests on a post hoc analysis of the CLASS data for patients who did not use aspirin. However, a similar retrospective approach to the data also reveals signs of increased cardiovascular risk.2
The final gastrointestinal-outcome study — the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) — was reported recently.3,4 TARGET compared lumiracoxib with naproxen or ibuprofen. The primary end point was the incidence of serious gastrointestinal events, which was reduced significantly among patients receiving lumiracoxib. However, this difference was only observed in patients who were not taking aspirin. Although the trial, much like the CLASS trial, was not powered to detect a difference in the rates of cardiovascular events in nonaspirin users, more such events occurred in the lumiracoxib group than in the other group (0.26 vs. 0.18 per 100 patient-years; hazard ratio, 1.47), although the difference was not significant.
No study of the gastrointestinal effects of valdecoxib treatment has been reported. However, in a study in patients undergoing coronary-artery bypass grafting,2 treatment with the valdecoxib prodrug, parecoxib, was associated with a cluster of cardiovascular events, and the drug was rejected by the FDA. Although parecoxib is effective as an analgesic only when it is converted to valdecoxib in vivo, and approval of the latter drug was based on studies in patients with low cardiovascular risk, the labeling of valdecoxib does not reflect the experience with parecoxib.
Finally, a series of epidemiologic analyses have also raised questions about the cardiovascular safety of the coxibs. Although the epidemiologic approach has commonly relied on databases of prescriptions and is particularly subject to bias due to the over-the-counter consumption of NSAIDs and aspirin, these studies broadened the context of the available evidence by relating risk to the dose of rofecoxib used.5
Before the results of the APPROVe study were released, the scientific evidence of gastrointestinal benefit from coxibs in the VIGOR and TARGET trials appeared to outweigh the evidence of cardiovascular risk. The FDA pursued a cautious policy, labeling celecoxib and rofecoxib in ways that reflected the outcomes of the CLASS and VIGOR trials. However, the APPROVe study has shifted the burden of proof. We now have clear evidence of an increase in cardiovascular risk that revealed itself in a manner consistent with a mechanistic explanation that extends to all the coxibs. It seems to be time for the FDA urgently to adjust its guidance to patients and doctors to reflect this new reality. Only the FDA can provide unbiased and informed guidance; it has a role to play beyond watchful waiting. In the absence of such guidance, what should physicians and their patients do? Selective inhibitors of COX-2 remain a rational choice for patients at a low cardiovascular risk who have had serious gastrointestinal events, especially while taking traditional NSAIDs. It would also seem prudent to avoid coxibs in patients who have cardiovascular disease or who are at risk for it.
The rofecoxib story also reflects poorly on the process that leads to drug approval. The rational basis for addressing the cardiovascular effects of these drugs has been clear for the past five years, yet even the most fundamental questions have not been addressed directly. Much information could have been derived from careful mechanistic studies in small numbers of patients and volunteers. However, drug companies are driven by the current requirements for drug approval to design studies such as TARGET. This most expensive and largest of the outcome studies involved exposing more than 18,000 patients to lumiracoxib for a year. It laid the foundation for the approval of another coxib, but it failed to address important questions about cardiovascular risk raised by the VIGOR trial and by mechanistic and epidemiologic studies.
Patients in the APPROVe study should continue to be followed. This will allow some estimate of how quickly the developed risk may dissipate. Given the relatively short half-lives of these compounds,2 such a dissipation may occur rapidly. On the other hand, if treatment has accelerated atherosclerosis, the offset of risk may be more gradual. Finally, it is essential to determine whether the cardiovascular risk is or is not a class effect. The burden of proof now rests with those who claim that this is a problem for rofecoxib alone and does not extend to other coxibs. We must remember that the absence of evidence is not the evidence of absence.
Dr. FitzGerald reports having received consulting fees from NiCox and Merck and research support from Merck.
Source Information
From the Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia.
- References
References
1
FitzGerald GA ,Patrono C . The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-442
Full Text | Web of Science | Medline2
FitzGerald GA . COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890
CrossRef | Web of Science | Medline3
Schnitzer TJ ,Burmester GR ,Mysler E , et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-674
CrossRef | Web of Science | Medline4
Farkouh ME ,Kirshner H ,Harrington RA , et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-684
CrossRef | Web of Science | Medline5
Ray WA ,Stein CM ,Daugherty JR ,Hall K ,Arbogast PG ,Griffin MR . COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-1073
CrossRef | Web of Science | Medline
- Citing Articles (237)
Citing Articles
1
Jatinder Kaur, Atul Bhardwaj, Zhangjian Huang, Edward E. Knaus. (2012) N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters
CrossRef2
Deepak Lokwani, Reecha Shah, Santosh Mokale, Padma Shastry, Devanand Shinde. (2012) Development of energetic pharmacophore for the designing of 1,2,3,4-tetrahydropyrimidine derivatives as selective cyclooxygenase-2 inhibitors. Journal of Computer-Aided Molecular Design
CrossRef3
Israel Rubinstein, Guy L. Weinberg. (2012) Nanomedicines for chronic non-infectious arthritis: The clinician's perspective. Maturitas
CrossRef4
Philip G. Conaghan. (2011) A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatology International
CrossRef5
Thor Hallingbye, Jacob Martin, Christopher Viscomi. (2011) Acute postoperative pain management in the older patient. Aging Health 7:6, 813-828
CrossRef6
Siegfried Schulz, Simone Ninke, Bernhard Watzer, Rolf Michael Nüsing. (2011) Ozone induces synthesis of systemic prostacyclin by cyclooxygenase-2 dependent mechanism in vivo. Biochemical Pharmacology
CrossRef7
Jatinder Kaur, Atul Bhardwaj, Zhangjian Huang, Edward E. Knaus. (2011) Aspirin Analogues as Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitors: Synthesis, Nitric Oxide Release, Molecular Modeling, and Biological Evaluation as Anti-Inflammatory Agents. ChemMedChemn/a-n/a
CrossRef8
Andrew Whelton, Allan Gibofsky. (2011) Minimizing Cardiovascular Complications During the Treatment of Osteoarthritis. American Journal of Therapeutics 18:6, 466-476
CrossRef9
Christine T. N. Pham. (2011) Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 3:6, 607-619
CrossRef10
Takako Hirata, Shuh Narumiya. (2011) Prostanoid Receptors. Chemical Reviews 111:10, 6209-6230
CrossRef11
Salvatore Genovese, Massimo Curini, Paolo Gresele, Teresa Corazzi, Francesco Epifano. (2011) Inhibition of COX-1 activity and COX-2 expression by 3-(4′-geranyloxy-3′-methoxyphenyl)-2-trans propenoic acid and its semi-synthetic derivatives. Bioorganic & Medicinal Chemistry Letters 21:19, 5995-5998
CrossRef12
Leandro Francisco Silva Bastos, Antônio Carlos Pinheiro de Oliveira, Johannes Carolus Magnus Schlachetzki, Bernd L. Fiebich. (2011) Minocycline reduces prostaglandin E synthase expression and 8-isoprostane formation in LPS-activated primary rat microglia. Immunopharmacology and Immunotoxicology 33:3, 576-580
CrossRef13
Anurag Maheshwari, Lohit Badgujar, Bonoranjan Phukan, Subhash Laxmanrao Bodhankar, Prasad Thakurdesai. (2011) Protective effect of Etoricoxib against middle cerebral artery occlusion induced transient focal cerebral ischemia in rats. European Journal of Pharmacology 667:1-3, 230-237
CrossRef14
Christian Fredrik Rushfeldt, Baldur Sveinbjørnsson, Kjetil Søreide, Barthold Vonen. (2011) Risk of anastomotic leakage with use of NSAIDs after gastrointestinal surgery. International Journal of Colorectal Disease
CrossRef15
Lingaiah Nagarapu, Jhansi Mateti, Hanmant K. Gaikwad, Rajashaker Bantu, M. Sheeba Rani, N.J. Prameela Subhashini. (2011) Synthesis and anti-inflammatory activity of some novel 3-phenyl-N-[3-(4-phenylpiperazin-1yl)propyl]-1H-pyrazole-5-carboxamide derivatives. Bioorganic & Medicinal Chemistry Letters 21:14, 4138-4140
CrossRef16
B.K. Sharma, P. Singh, P. Pilania, M. Shekhawat, Y.S. Prabhakar. (2011) QSAR of 2-(4-methylsulphonylphenyl)pyrimidine derivatives as cyclooxygenase-2 inhibitors: simple structural fragments as potential modulators of activity. Journal of Enzyme Inhibition and Medicinal Chemistry1-12
CrossRef17
Channarong Muangnoi, Pimjai Chingsuwanrote, Phawachaya Praengamthanachoti, Saovaros Svasti, Siriporn Tuntipopipat. (2011) Moringa oleifera Pod Inhibits Inflammatory Mediator Production by Lipopolysaccharide-Stimulated RAW 264.7 Murine Macrophage Cell Lines. Inflammation
CrossRef18
Arduino A Mangoni, Michael A Crilly, Kathleen M Knights. (2011) Cardiovascular toxicity of nonsteroidal anti-inflammatory drugs: moving beyond cyclooxygenase selectivity. Expert Review of Clinical Pharmacology 4:3, 299-302
CrossRef19
Stefano Fiorucci, Andrea Mencarelli, Sabrina Cipriani, Barbara Renga, Giuseppe Palladino, Luca Santucci, Eleonora Distrutti. (2011) Activation of the Bile Acid Sensor FXR Protects Against Gastrointestinal Injury Caused By ASA And NSAIDs in Mice. British Journal of Pharmacologyno-no
CrossRef20
Sung Hee Hwang, Karen M. Wagner, Christophe Morisseau, Jun-Yan Liu, Hua Dong, Aaron T. Wecksler, Bruce D. Hammock. (2011) Synthesis and Structure−Activity Relationship Studies of Urea-Containing Pyrazoles as Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide Hydrolase. Journal of Medicinal Chemistry 54:8, 3037-3050
CrossRef21
Siriporn Tuntipopipat, Channarong Muangnoi, Pimjai Chingsuwanrote, Montira Parengam, Pranom Chantravisut, Somsri Charoenkiatkul, Saovaros Svasti. (2011) Anti-inflammatory activities of red curry paste extract on lipopolysaccharide-activated murine macrophage cell line. Nutrition 27:4, 479-487
CrossRef22
Patricia McGettigan, Lisa F Lincz, John Attia, Patrick McElduff, Barrie Stokes, Linda Bissett, Roseanne Peel, Stephen Hancock, Kim Henderson, Michael Seldon, David Henry. (2011) The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene. British Journal of Clinical Pharmacologyno-no
CrossRef23
Timothy D. Warner, Sven Nylander, Carl Whatling. (2011) ANTI-PLATELET THERAPY: CYCLOOXYGENASE INHIBITION AND THE USE OF ASPIRIN WITH PARTICULAR REGARD TO DUAL ANTI-PLATELET THERAPY. British Journal of Clinical Pharmacologyno-no
CrossRef24
Stéphanie Gohin, Dominique Sigaudo-Roussel, Agnès Conjard-Duplany, Laurence Dubourg, Jean Louis Saumet, Bérengère Fromy. (2011) What Can Current Stimulation Tell Us about the Vascular Function of Endogenous Prostacyclin in Healthy Rat Skin In Vivo?. Journal of Investigative Dermatology 131:1, 237-244
CrossRef25
Ning Li, Jun-Yan Liu, Hong Qiu, Todd R. Harris, Padmini Sirish, Bruce D. Hammock, Nipavan Chiamvimonvat. (2011) Use of Metabolomic Profiling in the Study of Arachidonic Acid Metabolism in Cardiovascular Disease. Congestive Heart Failure 17:1, 42-46
CrossRef26
Eric Coomes, Edwin S. L. Chan, Allison B. Reiss. (2011) Methotrexate in Atherogenesis and Cholesterol Metabolism. Cholesterol 2011, 1-8
CrossRef27
Yisheng Lai, Lin Ma, Wenxing Huang, Xing Yu, Yihua Zhang, Hui Ji, Jide Tian. (2010) Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl)phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors. Bioorganic & Medicinal Chemistry Letters 20:24, 7349-7353
CrossRef28
Souhila Bouaziz-Terrachet, Amel Toumi-Maouche, Boubekeur Maouche, Safia Taïri-Kellou. (2010) Modeling the binding modes of stilbene analogs to cyclooxygenase-2: a molecular docking study. Journal of Molecular Modeling 16:12, 1919-1929
CrossRef29
John D Imig. (2010) Targeting Epoxides for Organ Damage in Hypertension. Journal of Cardiovascular Pharmacology 56:4, 329-335
CrossRef30
J.-Y. Liu, N. Li, J. Yang, N. Li, H. Qiu, D. Ai, N. Chiamvimonvat, Y. Zhu, B. D. Hammock. (2010) Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proceedings of the National Academy of Sciences 107:39, 17017-17022
CrossRef31
A. A. Mangoni, D. M. Reid, K. M. Knights. (2010) Non-steroidal anti-inflammatory drugs and atherothrombotic risk in older patients: where do we stand?. Age and Ageing 39:5, 530-533
CrossRef32
Anders Gabrielsen, Hong Qiu, Magnus Bäck, Mats Hamberg, Anne-Louise Hemdahl, Hanna Agardh, Lasse Folkersen, Jesper Swedenborg, Ulf Hedin, Gabrielle Paulsson-Berne, Jesper Z. Haeggström, Göran K. Hansson. (2010) Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. Journal of Molecular Medicine 88:8, 795-806
CrossRef33
Kyriakos N. Papanicolaou, John M. Streicher, Tomo-o Ishikawa, Harvey Herschman, Yibin Wang, Kenneth Walsh. (2010) Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. Journal of Molecular and Cellular Cardiology 49:2, 196-209
CrossRef34
William J. Elliott. (2010) Do the Blood Pressure Effects of Nonsteroidal Antiinflammatory Drugs Influence Cardiovascular Morbidity and Mortality?. Current Hypertension Reports 12:4, 258-266
CrossRef35
Arduino A. Mangoni, Richard J. Woodman, Paraskevi Gaganis, Andrew L. Gilbert, Kathleen M. Knights. (2010) Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. British Journal of Clinical Pharmacology 69:6, 689-700
CrossRef36
Hu Zhou, Wen Liu, Ying Su, Zhen Wei, Jie Liu, Siva Kumar Kolluri, Hua Wu, Yu Cao, Jiebo Chen, Yin Wu, Tingdong Yan, Xihua Cao, Weiwei Gao, Andrei Molotkov, Fuquan Jiang, Wen-Gang Li, Bingzhen Lin, Hai-Ping Zhang, Jinghua Yu, Shi-Peng Luo, Jin-Zhang Zeng, Gregg Duester, Pei-Qiang Huang, Xiao-Kun Zhang. (2010) NSAID Sulindac and Its Analog Bind RXRα and Inhibit RXRα-Dependent AKT Signaling. Cancer Cell 17:6, 560-573
CrossRef37
Warren A. Katz, Robert L. Barkin. (2010) Dilemmas in Chronic/Persistent Pain Management. Disease-a-Month 56:4, 233-250
CrossRef38
G. Enrico Rovati, Angelo Sala, Valérie Capra, Sven-Erik Dahlén, Giancarlo Folco. (2010) Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends in Pharmacological Sciences 31:3, 102-107
CrossRef39
Kohei Tanaka, Yasutaka Yamamoto, Shunsuke Tsujimoto, Naonori Uozumi, Yoshihiro Kita, Akio Yoshida, Takao Shimizu, Ichiro Hisatome. (2010) The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model. European Journal of Pharmacology 627:1-3, 223-228
CrossRef40
Tilo Grosser, Ying Yu, Garret A. FitzGerald. (2010) Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga. Annual Review of Medicine 61:1, 17-33
CrossRef41
Elizebeth C. Turner, B. Therese Kinsella. (2010) Estrogen Increases Expression of the Human Prostacyclin Receptor within the Vasculature through an ERα-Dependent Mechanism. Journal of Molecular Biology 396:3, 473-486
CrossRef42
Yiu-fai Cheung. 2010. Systemic Circulation. , 91-116.
CrossRef43
Antonio Strillacci, Cristiana Griffoni, Maria Chiara Valerii, Giorgia Lazzarini, Vittorio Tomasi, Enzo Spisni. (2010) RNAi-Based Strategies for Cyclooxygenase-2 Inhibition in Cancer. Journal of Biomedicine and Biotechnology 2010, 1-12
CrossRef44
Wonjae Lee, Jung-Won Suh, Han-Mo Yang, Dong-A Kwon, Hyun-Ju Cho, Hyun-Jae Kang, Hyo-Soo Kim, Byung-Hee Oh. (2010) Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers. Korean Circulation Journal 40:7, 321
CrossRef45
Arduino A. Mangoni, Richard J. Woodman, Andrew L. Gilbert, Kathleen M. Knights. (2010) Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef46
Wenlong Li, Jing Xu, Xiaojian Wang, Jingzhou Chen, Channa Zhang, Kai Sun, Rutai Hui. (2009) Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: A meta-analysis. Atherosclerosis 207:2, 492-495
CrossRef47
Siriporn Tuntipopipat, Channarong Muangnoi, Mark L. Failla. (2009) Anti-Inflammatory Activities of Extracts of Thai Spices and Herbs with Lipopolysaccharide-Activated RAW 264.7 Murine Macrophages. Journal of Medicinal Food 12:6, 1213-1220
CrossRef48
Fei-Yuan Hsiao, Yi-Wen Tsai, Weng-Foung Huang. (2009) Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: A retrospective study of physician-patient pairs in Taiwan. Clinical Therapeutics 31:11, 2618-2627
CrossRef49
Tatsuya Kaneshiro, Masae Okumura, Samer Maalouf, Andre Uflacker, Takayuki Maruyama, Toshihiko Kawamori. (2009) Inhibition of prostaglandin E2 signaling through the EP1 receptor does not affect prostacyclin production in human endothelial cells. Prostaglandins & Other Lipid Mediators 90:1-2, 31-36
CrossRef50
John D. Imig, Bruce D. Hammock. (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nature Reviews Drug Discovery 8:10, 794-805
CrossRef51
Eric E. Zhang, Andrew C. Liu, Tsuyoshi Hirota, Loren J. Miraglia, Genevieve Welch, Pagkapol Y. Pongsawakul, Xianzhong Liu, Ann Atwood, Jon W. Huss, Jeff Janes, Andrew I. Su, John B. Hogenesch, Steve A. Kay. (2009) A Genome-wide RNAi Screen for Modifiers of the Circadian Clock in Human Cells. Cell 139:1, 199-210
CrossRef52
E. Chilet-Rosell, M. T. Ruiz-Cantero, J. F. Horga. (2009) Women's health and gender-based clinical trials on etoricoxib: methodological gender bias. Journal of Public Health 31:3, 434-445
CrossRef53
Rajesh Rajaiah, David Y.-W. Lee, Zhongze Ma, Arthur Y. Fan, Lixing Lao, Harry H.S. Fong, Brian M. Berman, Kamal D. Moudgil. (2009) Huo-Luo-Xiao-Ling Dan modulates antigen-directed immune response in adjuvant-induced inflammation. Journal of Ethnopharmacology 123:1, 40-44
CrossRef54
Zsolt Kasza, Kristina M. Fetalvero, Min Ding, Robert J. Wagner, Klara Acs, Anthony K. Guzman, Karen L. Douville, Richard J. Powell, John Hwa, Kathleen A. Martin. (2009) Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. Journal of Molecular and Cellular Cardiology 46:5, 682-694
CrossRef55
Yves Rival, Laurence Puech, Thierry Taillandier, Nathalie Benéteau, Anne Rouquette, Fabrice Lestienne, Elisabeth Dupont-Passelaigue, Isabelle Le Roy, Jean-François Patoiseau, Didier Junquéro. (2009) PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells. European Journal of Pharmacology 606:1-3, 121-129
CrossRef56
L. Björklund, M.-A. Wallander, S. Johansson, E. Lesén. (2009) Aspirin in cardiology - benefits and risks. International Journal of Clinical Practice 63:3, 468-477
CrossRef57
N. L. Ambrose, P. O’Connell, G. Kearns. (2009) Limiting cardiovascular risk in Irish rheumatoid arthritis patients. Irish Journal of Medical Science 178:1, 53-55
CrossRef58
Muhammad A. Munir, Eli Cianciolo, Jun-Ming Zhang. 2009. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND CYCLOOXYGENASE-2 INHIBITORS. , 442-448.
CrossRef59
Michael Camilleri, Lin Chang. (2008) Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles. Gastroenterology 135:6, 1877-1891
CrossRef60
Regina Kleinert, Claudia Lange, Achim Steup, Peter Black, Jutta Goldberg, Paul Desjardins. (2008) Single Dose Analgesic Efficacy of Tapentadol in Postsurgical Dental Pain: The Results of a Randomized, Double-Blind, Placebo-Controlled Study. Anesthesia & Analgesia 107:6, 2048-2055
CrossRef61
Martina B. O'Keeffe, Helen M. Reid, B. Therese Kinsella. (2008) Agonist-dependent internalization and trafficking of the human prostacyclin receptor: A direct role for Rab5a GTPase. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1783:10, 1914-1928
CrossRef62
Anton Yuryev. (2008) In silico pathway analysis: the final frontier towards completely rational drug design. Expert Opinion on Drug Discovery 3:8, 867-876
CrossRef63
Christopher P. Cannon, Cong Chen, Sean P. Curtis, John Viscusi, Tuli Ahmed, Peter M. DiBattiste. (2008) A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Archives of Drug Information 1:1, 4-13
CrossRef64
R.E. Coleman, W.W. Bolten, M. Lansdown, S. Dale, C. Jackisch, D. Merkel, N. Maass, P. Hadji. (2008) Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treatment Reviews 34:3, 275-282
CrossRef65
Warren A Katz, Robert L Barkin. (2008) Dilemmas in Chronic/Persistent Pain Management. American Journal of Therapeutics 15:3, 256-264
CrossRef66
Allan Gibofsky, Robert L Barkin. (2008) Chronic Pain of Osteoarthritis: Considerations for Selecting an Extended-Release Opioid Analgesic. American Journal of Therapeutics 15:3, 241-255
CrossRef67
Nick Daneman, Donald E. Low, Alison McGeer, Karen A. Green, David N. Fisman. (2008) At the Threshold: Defining Clinically Meaningful Resistance Thresholds for Antibiotic Choice in Community‐Acquired Pneumonia. Clinical Infectious Diseases 46:8, 1131-1138
CrossRef68
V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, G. D. Kitas. (2008) Hypertension in rheumatoid arthritis. Rheumatology 47:9, 1286-1298
CrossRef69
Sérgio L Dalmora, Maximiliano S Sangoi, Micheli Wrasse, Raquel M Bernardi, Ricardo M Ferretto, Marcio Fronza. (2008) Evaluation of the changes in hemostatic parameters induced by etoricoxib in rat model. Blood Coagulation & Fibrinolysis 19:3, 254-257
CrossRef70
Aurelio Orjales, Ramón Mosquera, Beatriz López, Roberto Olivera, Luis Labeaga, M. Teresa Núñez. (2008) Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Bioorganic & Medicinal Chemistry 16:5, 2183-2199
CrossRef71
Shun Kohsaka, Kelly A. Volcik, Aaron R. Folsom, Kenneth K. Wu, Christie M. Ballantyne, James T. Willerson, Eric Boerwinkle. (2008) Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G−765C polymorphism in African-Americans: The Atherosclerosis Risk in Communities Study. Atherosclerosis 196:2, 926-930
CrossRef72
Vasileios F Panoulas, Holly John, George D Kitas. (2008) Six-step management of hypertension in patients with rheumatoid arthritis. Future Rheumatology 3:1, 21-35
CrossRef73
Takuro KANEKURA. (2008) Nishi Nihon Hifuka 70:6, 645-650
CrossRef74
Jenny Pettersson, Pernilla Christina Karlsson, Young Hae Choi, Robert Verpoorte, Joseph James Rafter, Lars Bohlin. (2008) NMR Metabolomic Analysis of Fecal Water from Subjects on a Vegetarian Diet. Biological & Pharmaceutical Bulletin 31:6, 1192-1198
CrossRef75
Vibeke Strand. (2007) Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. The Lancet 370:9605, 2138-2151
CrossRef76
Muhammad A. Munir, Nasr Enany, Jun-Ming Zhang. (2007) Nonopioid Analgesics. Anesthesiology Clinics 25:4, 761-774
CrossRef77
Gayle McKellar, Rajan Madhok, Gurkirpal Singh. (2007) The problem with NSAIDs: What data to believe?. Current Pain and Headache Reports 11:6, 423-427
CrossRef78
J. GRAFF, C. SKARKE, U. KLINKHARDT, B. WATZER, S. HARDER, H. SEYBERTH, G. GEISSLINGER, R. M. NÜSING. (2007) Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. Journal of Thrombosis and Haemostasis 5:12, 2376-2385
CrossRef79
Girish P. Joshi, Ralph Gertler, Ruth Fricker. (2007) Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesthesia & Analgesia 105:6, 1793-1804
CrossRef80
Katharina Lötzer, Steffen Jahn, Cornelia Kramer, Markus Hildner, Rolf Nüsing, Colin D. Funk, Andreas J.R. Habenicht. (2007) 5-Lipoxygenase/cyclooxygenase-2 cross-talk through cysteinyl leukotriene receptor 2 in endothelial cells. Prostaglandins & Other Lipid Mediators 84:3-4, 108-115
CrossRef81
A. S. TAHA, W. J. ANGERSON, R. PRASAD, C. MCCLOSKEY, O. BLATCHFORD. (2007) Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Alimentary Pharmacology & Therapeutics 26:8, 1171-1178
CrossRef82
J Stitham, E Arehart, S R Gleim, N Li, K Douville, J Hwa. (2007) New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues. British Journal of Pharmacology 152:4, 513-522
CrossRef83
Nipavan Chiamvimonvat, Chin-Min Ho, Hsing-Ju Tsai, Bruce D Hammock. (2007) The Soluble Epoxide Hydrolase as a Pharmaceutical Target for Hypertension. Journal of Cardiovascular Pharmacology 50:3, 225-237
CrossRef84
George A. Gale, Kanyawim Kirtikara, Pattama Pittayakhajonwut, Somsak Sivichai, Yodhathai Thebtaranonth, Chawanee Thongpanchang, Vanicha Vichai. (2007) In search of cyclooxygenase inhibitors, anti-Mycobacterium tuberculosis and anti-malarial drugs from Thai flora and microbes. Pharmacology & Therapeutics 115:3, 307-351
CrossRef85
Janet Woodcock, James Witter, Raymond A. Dionne. (2007) Stimulating the development of mechanism-based, individualized pain therapies. Nature Reviews Drug Discovery 6:9, 703-710
CrossRef86
Ajay Narasimha, Junji Watanabe, James A. Lin, Susan Hama, Robert Langenbach, Mohamad Navab, Alan M. Fogelman, Srinivasa T. Reddy. (2007) A novel anti-atherogenic role for COX-2—potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins & Other Lipid Mediators 84:1-2, 24-33
CrossRef87
R.W. Moskowitz, S.B. Abramson, F. Berenbaum, L.S. Simon, M. Hochberg. (2007) Coxibs and NSAIDs – Is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis and Cartilage 15:8, 849-856
CrossRef88
Yen-Hwang Chuang, Wan-Long Chuang, Shu-Pin Huang, Chun-Hsiung Huang. (2007) Cyclooxygenase-2 inhibitor ameliorates ureteric damage in rats with obstructed uropathy. European Journal of Pharmacology 569:1-2, 126-137
CrossRef89
Jeremiah Stitham, Eric J. Arehart, Scott Gleim, Karen Douville, Todd MacKenzie, John Hwa. (2007) Arginine (CGC) codon targeting in the human prostacyclin receptor gene (PTGIR) and G-protein coupled receptors (GPCR). Gene 396:1, 180-187
CrossRef90
A M Feldman, W J Koch, T L Force. (2007) Developing Strategies to Link Basic Cardiovascular Sciences with Clinical Drug Development: Another Opportunity for Translational Sciences. Clinical Pharmacology & Therapeutics 81:6, 887-892
CrossRef91
M R Miller, I L Megson. (2007) Recent developments in nitric oxide donor drugs. British Journal of Pharmacology 151:3, 305-321
CrossRef92
Anna Maria Buccoliero, Francesca Castiglione, Duccio Rossi Degl??Innocenti, Luisa Arganini, Antonio Taddei, Franco Ammannati, Pasquale Mennonna, Gian Luigi Taddei. (2007) Cyclooxygenase-2 (COX-2) Overexpression in Meningiomas. Applied Immunohistochemistry & Molecular Morphology 15:2, 187-192
CrossRef93
Jonathan Afilalo, Michael J. Coussa-Charley, Mark J. Eisenberg. (2007) Long-term Risk of Ischemic Stroke Associated with Rofecoxib. Cardiovascular Drugs and Therapy 21:2, 117-120
CrossRef94
Frank Andersohn. (2007) Cerebrovascular Events After Discontinuation of Rofecoxib Treatment. Cardiovascular Drugs and Therapy 21:2, 77-79
CrossRef95
Kenneth K. Wu. (2007) Differential cyclooxygenase-2 transcriptional control in proliferating versus quiescent fibroblasts. Prostaglandins & Other Lipid Mediators 83:3, 175-181
CrossRef96
Alicia Prieto, Manuel De Barrio, Elena Martín, María Fernández-Bohórquez, Francisco Javier de Castro, Francisco Javier Ruiz, Teresa Herrero, Pilar Tornero, María Rubio. (2007) Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. Journal of Allergy and Clinical Immunology 119:4, 960-964
CrossRef97
Zahi Touma, Lan Chen, Thurayya Arayssi. (2007) Topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. Future Rheumatology 2:2, 163-175
CrossRef98
James B. Moberly, Jianbo Xu, Paul J. Desjardins, Stephen E. Daniels, Donald P. Bandy, Janet E. Lawson, Allison J. Link, Kenneth E. Truitt. (2007) A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain. Clinical Therapeutics 29:3, 399-412
CrossRef99
Cristiana Griffoni, Enzo Spisni, Antonio Strillacci, Mattia Toni, Markus Michael Bachschmid, Vittorio Tomasi. (2007) Selective inhibition of prostacyclin synthase activity by rofecoxib. Journal of Cellular and Molecular Medicine 11:2, 327-338
CrossRef100
Gregory D. Ferguson, Kristen Jensen-Pergakes, Candice Wilkey, Urvi Jhaveri, Normand Richard, Dominique Verhelle, Laure Moutouh Parseval, Laura G. Corral, Weilin Xie, Christopher L. Morris, Helen Brady, Kyle Chan. (2007) Immunomodulatory Drug CC-4047 is a Cell-type and Stimulus-Selective Transcriptional Inhibitor of Cyclooxygenase 2. Journal of Clinical Immunology 27:2, 210-220
CrossRef101
Scott D Solomon. (2007) Cyclooxygenase-2 inhibitors and cardiovascular risk. Current Opinion in Internal Medicine 6:1, 26-30
CrossRef102
m. camilleri. (2007) Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT 3 antagonist treatment?. Neurogastroenterology & Motility 19:2, 77-84
CrossRef103
Yong I. Cha, Raymond N. DuBois. (2007) NSAIDs and Cancer Prevention: Targets Downstream of COX-2. Annual Review of Medicine 58:1, 239-252
CrossRef104
Bob H. Sun, Christopher W. Wu, Kenneth C. Kalunian. (2007) New Developments in Osteoarthritis. Rheumatic Disease Clinics of North America 33:1, 135-148
CrossRef105
Sabine Brouxhon, Raymond L Konger, JoAnne VanBuskirk, Tzong-jen Sheu, Julie Ryan, Brandon Erdle, Anthony Almudevar, Richard M Breyer, Glynis Scott, Alice P Pentland. (2007) Deletion of Prostaglandin E2 EP2 Receptor Protects against Ultraviolet-Induced Carcinogenesis, but Increases Tumor Aggressiveness. Journal of Investigative Dermatology 127:2, 439-446
CrossRef106
R D Verschoyle, P Greaves, H Cai, R E Edwards, W P Steward, A J Gescher. (2007) Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis. British Journal of Cancer 96:2, 248-254
CrossRef107
L Gallelli, M Colosimo, D Pirritano, M Ferraro, S De Fazio, N M Marigliano, G De Sarro. (2007) Retrospective Evaluation of Adverse??Drug Reactions Induced??by??Nonsteroidal Anti-Inflammatory Drugs. Clinical Drug Investigation 27:2, 115-122
CrossRef108
Andrew Miller, Andrew McKee, C. David Mazer. 2007. Sedation, Analgesia, and Related Topics. , 53-70.
CrossRef109
Muhammad A. Munir, Nasr Enany, Jun-Ming Zhang. (2007) Nonopioid Analgesics. Medical Clinics of North America 91:1, 97-111
CrossRef110
Jeremiah Stitham, Eric J. Arehart, Scott R. Gleim, Karen L. Douville, John Hwa. (2007) Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins & Other Lipid Mediators 82:1-4, 95-108
CrossRef111
Shyam S Bansal, Abhijeet Joshi, Arvind K Bansal. (2007) New Dosage Formulations for Targeted Delivery of Cyclo-Oxygenase-2 Inhibitors. Drugs & Aging 24:6, 441-451
CrossRef112
Ying Yu, Colin D. Funk. (2007) A novel genetic model of selective COX-2 inhibition: Comparison with COX-2 null mice. Prostaglandins & Other Lipid Mediators 82:1-4, 77-84
CrossRef113
Edward H.C. Wong, Thomas W.H. Leung, K.S. Lawrence Wong. (2007) Stroke Caused by Small Vessel Occlusion in a Patient Taking Etoricoxib and Thalidomide. Journal of Neuroimaging 17:1, 87-88
CrossRef114
Richard O Day, Kenneth M Williams. (2007) Open-Label Extension Studies. Drug Safety 30:2, 93-105
CrossRef115
Fabrizio Montecucco, Sabine Steffens, François Mach. (2007) The Immune Response Is Involved in Atherosclerotic Plaque Calcification: Could the RANKL/RANK/OPG System Be a Marker of Plaque Instability?. Clinical and Developmental Immunology 2007, 1-8
CrossRef116
Catriona M Turnbull, Adriano G Rossi, Ian L Megson. (2006) Therapeutic effects of nitric oxide-aspirin hybrid drugs. Expert Opinion on Therapeutic Targets 10:6, 911-922
CrossRef117
Mohammad Al-Fayez, Hong Cai, Richard Tunstall, William P. Steward, Andreas J. Gescher. (2006) Differential modulation of cyclooxygenase-mediated prostaglandin production by the putative cancer chemopreventive flavonoids tricin, apigenin and quercetin. Cancer Chemotherapy and Pharmacology 58:6, 816-825
CrossRef118
Japie A Louw. (2006) Peptic ulcer disease. Current Opinion in Gastroenterology 22:6, 607-611
CrossRef119
Joseph C. Maroon, Jeffrey W. Bost, Meghan K. Borden, Keith M. Lorenz, Nathan A. Ross. (2006) Natural antiinflammatory agents for pain relief in athletes. Neurosurgical FOCUS 21:4, 1-13
CrossRef120
Majella E. Lane, Mi-Jeong Kim. (2006) Assessment and prevention of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Journal of Pharmacy and Pharmacology 58:10, 1295-1304
CrossRef121
Jan Steffel, Alexander Akhmedov, Carine Fähndrich, Frank Ruschitzka, Thomas F. Lüscher, Felix C. Tanner. (2006) Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochemical and Biophysical Research Communications 349:2, 597-603
CrossRef122
Tai-Juan Aw, Danny Liew, Geoffrey H Tofler, Hans G Schneider, Marie-Christine Morel-Kopp, Baki Billah, Henry Krum. (2006) Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?. Journal of Hypertension 24:10, 1979-1984
CrossRef123
Theoharis C. Theoharides. 2006. Synovial Mast Cells in Inflammatory Arthritis. .
CrossRef124
K. R. Schmelzer, B. Inceoglu, L. Kubala, I.-H. Kim, S. L. Jinks, J. P. Eiserich, B. D. Hammock. (2006) Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proceedings of the National Academy of Sciences 103:37, 13646-13651
CrossRef125
D. Williams, M. Singh, C. Hind. (2006) The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. British Journal of Clinical Pharmacology 62:3, 366-368
CrossRef126
Hao-Wei Wang, Chung-Tsen Hsueh, Chien-Fu Jeff Lin, Teh-Ying Chou, Wen-Hu Hsu, Liang-Shun Wang, Yu-Chung Wu. (2006) Clinical Implications of Microsomal Prostaglandin E Synthase-1 Overexpression in Human Non–Small-Cell Lung Cancer. Annals of Surgical Oncology 13:9, 1224-1234
CrossRef127
Siew Siang Chua, Claire Devi Ramachandran, Thomas T Paraidathathu. (2006) Response of community pharmacists to the presentation of back pain: a simulated patient study. International Journal of Pharmacy Practice 14:3, 171-178
CrossRef128
Serenella Rotondo, Giuseppe Dell'Elba, Stefano Manarini, Chiara Cerletti, Virgilio Evangelista. (2006) The lipoxygenase–cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit. European Journal of Pharmacology 546:1-3, 95-101
CrossRef129
(2006) Guía sobre el manejo de la angina estable. Versión resumida. Revista Española de Cardiología 59:9, 919-970
CrossRef130
Göran K. Hansson, Peter Libby. (2006) The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology 6:7, 508-519
CrossRef131
Ying Yu, Jinjin Fan, Xin-Sheng Chen, Dairong Wang, Andres J Klein-Szanto, Robert L Campbell, Garret A FitzGerald, Colin D Funk. (2006) Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nature Medicine 12:6, 699-704
CrossRef132
S. Grosch, T. J. Maier, S. Schiffmann, G. Geisslinger. (2006) Cyclooxygenase-2 (COX-2)-Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. JNCI Journal of the National Cancer Institute 98:11, 736-747
CrossRef133
C. J. Hawkey, G. M. Hawkey, S. Everitt, M. M. Skelly, W. A. Stack, D. Gray. (2006) Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 61:6, 730-737
CrossRef134
Sue Haupt, Tamar Zioni, Irith Gati, Jackie Kleinstern, Abraham Rubinstein. (2006) Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. European Journal of Pharmaceutical Sciences 28:3, 204-211
CrossRef135
Hilal Maradit Kremers, Sherine E. Gabriel. (2006) Rheumatoid arthritis and the heart. Current Heart Failure Reports 3:2, 57-63
CrossRef136
Nurullah Akkoc, Sjef van der Linden, Muhammad Asim Khan. (2006) Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Practice & Research Clinical Rheumatology 20:3, 539-557
CrossRef137
NIALL M. CORCORAN, ANTHONY J. COSTELLO, CHRISTOPHER M. HOVENS. (2006) Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU International 97:6, 1149-1153
CrossRef138
A Strillacci, C Griffoni, E Spisni, M C Manara, V Tomasi. (2006) RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells. British Journal of Cancer 94:9, 1300-1310
CrossRef139
Noel G. Carlson, Kenneth E. Hill, Ikuo Tsunoda, Robert S. Fujinami, John W. Rose. (2006) The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: Implications for multiple sclerosis. Journal of Neuroimmunology 174:1-2, 21-31
CrossRef140
C. Kneitz, H. P. Tony, K. Krüger. (2006) NSAR und Coxibe: aktueller Stand. Der Internist 47:5, 533-540
CrossRef141
Nabih M Ramadan. (2006) Can lumiracoxib safely and effectively treat episodic tension-type headache?. Nature Clinical Practice Neurology 2:5, 242-243
CrossRef142
Francesco Cipollone, Maria Luigia Fazia. (2006) Cyclooxygenase-2 inhibition: Vascular inflammation and cardiovascular risk. Current Atherosclerosis Reports 8:3, 245-251
CrossRef143
Carlo Patrono. (2006) The PGH-Synthase System and Isozyme-selective Inhibition. Journal of Cardiovascular Pharmacology 47:Supplement 1, S1-S6
CrossRef144
Arnold B. Alper, Holly Tomlin, Usha Sadhwani, Andrew Whelton, Jules Puschett. (2006) Effects of the Selective Cyclooxygenase-2 Inhibitor Analgesic Celecoxib on Renal Carbonic Anhydrase Enzyme Activity: A Randomized, Controlled Trial. American Journal of Therapeutics 13:3, 229-235
CrossRef145
Axel H. Schönthal. (2006) Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurgical FOCUS 20:4, E21
CrossRef146
Ulrike Puhlmann, Dirk Schäfer, Christina Ziemann. (2006) Update on COX-2 inhibitor patents with a focus on optimised formulation and therapeutic scope of drug combinations making use of COX-2 inhibitors. Expert Opinion on Therapeutic Patents 16:4, 403-430
CrossRef147
Siobhan O'Donnell, Ann Cranney, Mary J. Jacobsen, Ian D. Graham, Annette M. O'Connor, Peter Tugwell. (2006) Understanding and overcoming the barriers of implementing patient decision aids in clinical practice*. Journal of Evaluation in Clinical Practice 12:2, 174-181
CrossRef148
Ellen Niederberger, Christine Manderscheid, Gerd Geisslinger. (2006) Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib. Biochemical and Biophysical Research Communications 342:3, 940-948
CrossRef149
Hans-Christoph Diener, Christian Lampl, Peter Reimnitz, Michael Voelker. (2006) Aspirin in the treatment of acute migraine attacks. Expert Review of Neurotherapeutics 6:4, 563-573
CrossRef150
Ramani R. Ranatunge, Michael E. Augustyniak, Vijay Dhawan, James L. Ellis, David S. Garvey, David R. Janero, L. Gordon Letts, Stewart K. Richardson, Mathew J. Shumway, A. Mark Trocha, Delano V. Young, Irina S. Zemtseva. (2006) Synthesis and anti-inflammatory activity of a series of N-substituted naproxen glycolamides: Nitric oxide-donor naproxen prodrugs. Bioorganic & Medicinal Chemistry 14:8, 2589-2599
CrossRef151
Sven-Erik Dahlén. (2006) Treatment of asthma with antileukotrienes: First line or last resort therapy?. European Journal of Pharmacology 533:1-3, 40-56
CrossRef152
E. Alpert, A. Gruzman, B. Lardi-Studler, G. Cohen, R. Reich, S. Sasson. (2006) Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKα-independent manner. Diabetologia 49:3, 562-570
CrossRef153
Yong I. Cha, Raymond N. DuBois. (2006) Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling: Recent advances in basic biology. Current Colorectal Cancer Reports 2:2, 60-65
CrossRef154
Sonia Hernandez-Diaz, Cristina Varas-Lorenzo, Luis A. Garcia Rodriguez. (2006) Non-Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction. Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology 98:3, 266-274
CrossRef155
Elizabeth J. Dial, J. Rand Doyen, Lenard M. Lichtenberger. (2006) Phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro. Cancer Chemotherapy and Pharmacology 57:3, 295-300
CrossRef156
Felson, David T., . (2006) Osteoarthritis of the Knee. New England Journal of Medicine 354:8, 841-848
Full Text157
Alex Yui Hui, Wai Keung Leung, Henry Lik Yuen Chan, Francis Ka Leung Chan, Minnie Yin Yin Go, Ka Kui Chan, Bao Dong Tang, Eagle Siu Hong Chu, Joseph Jao Yiu Sung. (2006) Effect of celecoxib on experimental liver fibrosis in rat. Liver International 26:1, 125-136
CrossRef158
Cornelia M. Ulrich, Jeannette Bigler, John D. Potter. (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Reviews Cancer 6:2, 130-140
CrossRef159
Tong Wu. (2006) Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treatment Reviews 32:1, 28-44
CrossRef160
Luis Romundstad, Harald Breivik, Helge Roald, Knut Skolleborg, Torleiv Haugen, Jon Narum, Audun Stubhaug. (2006) Methylprednisolone Reduces Pain, Emesis, and Fatigue After Breast Augmentation Surgery: A Single-Dose, Randomized, Parallel-Group Study with Methylprednisolone 125 mg, Parecoxib 40 mg, and Placebo. Anesthesia & Analgesia 102:2, 418-425
CrossRef161
Alastair J.M. Watson. (2006) An overview of apoptosis and the prevention of colorectal cancer. Critical Reviews in Oncology/Hematology 57:2, 107-121
CrossRef162
Francesco Cipollone, Maria Luigia Fazia, Andrea Mezzetti. (2006) Role of angiotensin II receptor blockers in atherosclerotic plaque stability. Expert Opinion on Pharmacotherapy 7:3, 277-285
CrossRef163
Jane A. Mitchell, Timothy D. Warner. (2006) COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature Reviews Drug Discovery 5:1, 75-86
CrossRef164
G. TREIBER, T. WEX, A. LINK, M. VIETH, S. LAUFER, P. MALFERTHEINER. (2006) The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa. Alimentary Pharmacology and Therapeutics 23:1, 155-167
CrossRef165
Gustav Born, Carlo Patrono. (2006) Antiplatelet drugs. British Journal of Pharmacology 147:S1, S241-S251
CrossRef166
Donald A. Dibbern. (2006) Urticaria: Selected Highlights and Recent Advances. Medical Clinics of North America 90:1, 187-209
CrossRef167
Michael Hoffmeister, Jenny Chang-Claude, Hermann Brenner. (2006) Do Older Adults Using NSAIDs Have a Reduced Risk of Colorectal Cancer?. Drugs & Aging 23:6, 513-523
CrossRef168
J??rgen N??sdal, Kurt Brown. (2006) NSAID-Associated Adverse Effects and Acid Control Aids to Prevent Them. Drug Safety 29:2, 119-132
CrossRef169
Katharina Benita Sokoll, Philip Helliwell. (2006) Pharmacological management of transient synovitis. Expert Opinion on Pharmacotherapy 7:1, 35-46
CrossRef170
Hee-Chun Kim. (2006) Nonsurgical Treatment of Osteoarthritis. Journal of the Korean Medical Association 49:5, 457
CrossRef171
Bin Zhang, Xiao-Li He, Yi Ding, Guan-Hua Du. (2006) Gaultherin, a natural salicylate derivative from Gaultheria yunnanensis: Towards a better non-steroidal anti-inflammatory drug. European Journal of Pharmacology 530:1-2, 166-171
CrossRef172
Stephen J. Genuis. (2006) Diagnosis: contemporary medical hubris; Rx: a tincture of humility. Journal of Evaluation in Clinical Practice 12:1, 24-30
CrossRef173
Noriko Ueno, Yui Takegoshi, Daisuke Kamei, Ichiro Kudo, Makoto Murakami. (2005) Coupling between cyclooxygenases and terminal prostanoid synthases. Biochemical and Biophysical Research Communications 338:1, 70-76
CrossRef174
Paul Bentley, Pankaj Sharma. (2005) Pharmacological treatment of ischemic stroke. Pharmacology & Therapeutics 108:3, 334-352
CrossRef175
Robert J. Kaplan. (2005) Current Status of NonsteroidalAnti-Inflammatory Drugsin Physiatry. American Journal of Physical Medicine & Rehabilitation 84:11, 885-894
CrossRef176
Danny Liew, Henry Krum. (2005) The cardiovascular safety of celecoxib. Future Cardiology 1:6, 709-722
CrossRef177
Torben Dybdahl, Morten Andersen, Jakob Kragstrup, Ivar Sonbo Kristiansen, Jens Sondergaard. (2005) General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study. British Journal of Clinical Pharmacology 60:5, 526-533
CrossRef178
Sara A. Quandt, Haiying Chen, Joseph G. Grzywacz, Ronny A. Bell, Wei Lang, Thomas A. Arcury. (2005) Use of complementary and alternative medicine by persons with arthritis: Results of the National Health Interview Survey. Arthritis & Rheumatism 53:5, 748-755
CrossRef179
Amos B. Smith, Qiang Han, Paul A. S. Breslin, Gary K. Beauchamp. (2005) Synthesis and Assignment of Absolute Configuration of (−)-Oleocanthal: A Potent, Naturally Occurring Non-steroidal Anti-inflammatory and Anti-oxidant Agent Derived from Extra Virgin Olive Oils. Organic Letters 7:22, 5075-5078
CrossRef180
Christianne L. Roumie, Patrick G. Arbogast, Edward F. Mitchel, Marie R. Griffin. (2005) Prescriptions for Chronic High-Dose Cyclooxygenase-2 Inhibitors are Often Inappropriate and Potentially Dangerous. Journal of General Internal Medicine 20:10, 879-883
CrossRef181
A. Brack, H. L. Rittner, M. Schäfer. (2005) Kritische Neubewertung von Zyklooxygenase-2-Inhibitoren in der perioperativen Schmerztherapie. Der Anaesthesist 54:10, 1032-1038
CrossRef182
Rei Shibata, Kaori Sato, David R Pimentel, Yukihiro Takemura, Shinji Kihara, Koji Ohashi, Tohru Funahashi, Noriyuki Ouchi, Kenneth Walsh. (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanisms. Nature Medicine 11:10, 1096-1103
CrossRef183
Helene Francois, Krairerk Athirakul, David Howell, Rajesh Dash, Lan Mao, Hyung-Suk Kim, Howard A. Rockman, Garret A. FitzGerald, Beverly H. Koller, Thomas M. Coffman. (2005) Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metabolism 2:3, 201-207
CrossRef184
John L. Wallace, Octavio Menezes de Lima, Stefano Fiorucci. (2005) Lipoxins in gastric mucosal health & disease. Prostaglandins, Leukotrienes and Essential Fatty Acids 73:3-4, 251-255
CrossRef185
Mack N. Barnes, David F. Chhieng, Mackenzie Dreher, Jennifer L. Jones, William E. Grizzle, Laura Jones, Lynya Talley, Edward E. Partridge. (2005) Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: Initial examination of celecoxib as a chemopreventive agent. Gynecologic Oncology 98:3, 376-382
CrossRef186
Matthew D. Breyer. (2005) Getting to the heart of COX-2 inhibition. Cell Metabolism 2:3, 149-150
CrossRef187
A. S. TAHA, W. J. ANGERSON, R. P. KNILL-JONES, O. BLATCHFORD. (2005) Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics 22:4, 285-289
CrossRef188
M. Atik. (2005) A Proposal for Evaluation of Platelet Aggregation and Adhesiveness for Clinical Trials with Cyclooxygenase Inhibitors and Nonsteroidal Antiinflammatory Drugs. Journal of the American College of Surgeons 201:2, 263-264
CrossRef189
Patrice Matchaba, Xavier Gitton, Gerhard Krammer, Elena Ehrsam, Victor Schorr Sloan, Melvin Olson, Bernhard Mellein, Godehard Hoexter, John Orloff, Jean-Jacques Garaud. (2005) Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clinical Therapeutics 27:8, 1196-1214
CrossRef190
Dirk Duppen. (2005) Wetenschapsfilosofie en commerciële belangen in het debat over evidence-based geneeskunde. Huisarts en Wetenschap 48:8, 451-454
CrossRef191
Elliot V. Hersh, Edward T. Lally, Paul A. Moore. (2005) Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?*. Current Medical Research and Opinion 21:8, 1217-1226
CrossRef192
D. PEREG, M. LISHNER. (2005) Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. Journal of Internal Medicine 258:2, 115-123
CrossRef193
Matthew Foster, Ralph Kendall, Mary Todd. (2005) COX-2 Inhibitor Safety in the Workers?? Compensation Market. Lippincott's Case Management 10:4, 217???220
CrossRef194
Tong Wu. (2005) Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1755:2, 135-150
CrossRef195
Alasdair Breckenridge, Kent Woods, June Raine. (2005) Essay: Monitoring the safety of licensed medicines. Nature Reviews Drug Discovery 4:7, 541-543
CrossRef196
R. De Caterina, M. Massaro. (2005) Omega-3 Fatty Acids and the Regulation of Expression of Endothelial Pro-Atherogenic and Pro-Inflammatory Genes. Journal of Membrane Biology 206:2, 103-116
CrossRef197
Bernard Hirschel. (2005) Effect of rimonabant on weight reduction and cardiovascular risk. The Lancet 366:9483, 369
CrossRef198
Maureen P. Flattery, Leigh Anne Hylton Gravatt. (2005) COX-2 Inhibitors and Cardiovascular Risk. Progress in Cardiovascular Nursing 20:3, 123-125
CrossRef199
Kenneth Khamly, Michael Jefford, Michael Michael, John Zalcberg. (2005) Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opinion on Investigational Drugs 14:6, 607-628
CrossRef200
Emmanuel Marret, Okba Kurdi, Paul Zufferey, Francis Bonnet. (2005) Effects of Nonsteroidal Antiinflammatory Drugs on Patient-controlled Analgesia Morphine Side Effects. Anesthesiology 102:6, 1249-1260
CrossRef201
Nathalie Richard, Debora Porath, Alexander Radspieler, Joseph Schwager. (2005) Effects of resveratrol, piceatannol, tri-acetoxystilbene, and genistein on the inflammatory response of human peripheral blood leukocytes. Molecular Nutrition & Food Research 49:5, 431-442
CrossRef202
Masanobu Oshima, Hiroko Oshima, Makoto M. Taketo. (2005) Hypergravity induces expression of cyclooxygenase-2 in the heart vessels. Biochemical and Biophysical Research Communications 330:3, 928-933
CrossRef203
Thomas J. Montine, Jason D. Morrow. (2005) Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease. The American Journal of Pathology 166:5, 1283-1289
CrossRef204
Rosemarie A Reiter, Bernd Jilma. (2005) Platelets and new antiplatelet drugs. Therapy 2:3, 465-502
CrossRef205
Madhumathi Rao, Bertrand L. Jaber, Vaidyanathapuram S. Balakrishnan, . (2005) Genetics in Dialysis
Series Editors: Bertrand L. Jaber and Vaidyanathapuram S. Balakrishnan: Gene Polymorphism Association Studies in Dialysis: Cardiovascular Disease. Seminars in Dialysis 18:3, 217-225
CrossRef206
Philip F. Halloran, Bruce Kaplan. (2005) Evolving Issues in Clinical Research. American Journal of Transplantation 5:4, 637-638
CrossRef207
W. K
ster. (2005) Therapie chronischer Schmerzen in der internistischen Praxis. Der Internist 46:4, 433-446
CrossRef208
Ying Yu, Yan Cheng, Jinjin Fan, Xin-Sheng Chen, Andres Klein-Szanto, Garret A. FitzGerald, Colin D. Funk. (2005) Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. Journal of Clinical Investigation 115:4, 986-995
CrossRef209
Thomas J. Montine. (2005) Symposium. Brain Pathology 15:2, 133-133
CrossRef210
Reiner Lehmann, Marek Brzosko, Petr Kopsa, Ruth Nischik, Andreas Kreiss, Helen Thurston, Stephane Litschig, Victor S. Sloan. (2005) Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Current Medical Research and Opinion 21:4, 517-526
CrossRef211
Feng-Shiun Shie, Kathleen S. Montine, Richard M. Breyer, Thomas J. Montine. (2005) Microglial EP2 as a New Target to Increase Amyloid β Phagocytosis and Decrease Amyloid β-Induced Damage to Neurons. Brain Pathology 15:2, 134-138
CrossRef212
Nussmeier, Nancy A., Whelton, Andrew A., Brown, Mark T., Langford, Richard M., Hoeft, Andreas, Parlow, Joel L., Boyce, Steven W., Verburg, Kenneth M., . (2005) Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. New England Journal of Medicine 352:11, 1081-1091
Full Text213
Solomon, Scott D., McMurray, John J.V., Pfeffer, Marc A., Wittes, Janet, Fowler, Robert, Finn, Peter, Anderson, William F., Zauber, Ann, Hawk, Ernest, Bertagnolli, Monica, . (2005) Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. New England Journal of Medicine 352:11, 1071-1080
Full Text214
(2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:3, i-xii
CrossRef215
Sheila A Doggrell. (2005) The safety of lumiracoxib when used in the treatment of arthritis. Expert Opinion on Pharmacotherapy 6:2, 347-350
CrossRef216
Leleti Rajender Reddy, E.J. Corey. (2005) Facile air oxidation of the conjugate base of rofecoxib (Vioxx™), a possible contributor to chronic human toxicity. Tetrahedron Letters 46:6, 927-929
CrossRef217
Ronald Esser, Carol Berry, Zhengming Du, Janet Dawson, Alyson Fox, Roger A Fujimoto, William Haston, Earl F Kimble, Julie Koehler, Jane Peppard, Elizabeth Quadros, Joseph Quintavalla, Karen Toscano, Laszlo Urban, John Duzer, Xiaoli Zhang, Siyuan Zhou, Paul J Marshall. (2005) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. British Journal of Pharmacology 144:4, 538-550
CrossRef218
David J. Triggle. (2005) Vaccines, Viagra, and Vioxx: medicines, markets, and money—when life-saving meets life-style. Drug Development Research 64:2, 90-98
CrossRef219
Xavier Carn
CrossRef220
Simon Frantz. (2005) Dangerous drugs?. news@nature
CrossRef221
Monica Schaefer, Melissa DeLattre, Xin Gao, Jennifer Stephens, Marc Botteman, Anthony Morreale. (2005) Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Current Medical Research and Opinion 21:1, 47-60
CrossRef222
Marc Fajardo, Paul E Di Cesare. (2005) Disease-Modifying Therapies for Osteoarthritis. Drugs & Aging 22:2, 141-161
CrossRef223
Yasushi Obase, Hiroto Matsuse, Terufumi Shimoda, Tari Haahtela, Shigeru Kohno. (2005) Pathogenesis and Management of Aspirin-Intolerant Asthma. Treatments in Respiratory Medicine 4:5, 325-336
CrossRef224
Joo-Heon Yoon, Seung Joon Baek. (2005) Molecular Targets of Dietary Polyphenols with Anti-inflammatory Properties. Yonsei Medical Journal 46:5, 585
CrossRef225
M. Labetoulle. (2005) Le retrait du Vioxx™ : des leçons pour tous. Journal Français d'Ophtalmologie 28:1, 126-127
CrossRef226
Bernard Bannwarth. (2005) Do Selective Cyclo-Oxygenase-2 Inhibitors Have a Future?. Drug Safety 28:3, 183-189
CrossRef227
Elizabeth J. Westgate, Garret A. FitzGerald. (2005) Pulmonary Embolism in a Woman Taking Oral Contraceptives and Valdecoxib. PLoS Medicine 2:7, e197
CrossRef228
Eric Sheldon, Andre Beaulieu, Zorba Paster, Dipen Dutta, Sue Yu, Victor S. Sloan. (2005) Efficacy and tolerability of lumiracoxib in the treatmentof osteoarthritis of the knee: A 13-week, randomized, double-blind comparison with celecoxib and placebo. Clinical Therapeutics 27:1, 64-77
CrossRef229
Ken Shinmura. (2005) Possible mechanisms of cyclooxygenase (COX)-2 hazard: Is COX-2 in the cardiovascular system a friend or a foe?. Ensho Saisei 25:6, 517-524
CrossRef230
Stuart J Warden. (2005) Cyclo-Oxygenase-2 Inhibitors. Sports Medicine 35:4, 271-283
CrossRef231
Andrew Whelton. (2005) Appropriate Analgesia: An Evidence-based Evaluation of the Role of Acetaminophen in Pain Management. American Journal of Therapeutics 12:1, 43-45
CrossRef232
D. R. Blake, N. Shenker, H. Cohen, C. R. Stevens. (2005) What if Derek Willoughby were right? Cyclo-oxygenase is an anti-inflammatory enzyme. InflammoPharmacology 12:5-6, 465-471
CrossRef233
Susan Burgin. (2005) New Drugs, New Rashes: Update on Cutaneous Drug Reactions. Advances in Dermatology 21, 279-302
CrossRef234
Scott A Paluska. (2005) An Overview of Hip Injuries in Running. Sports Medicine 35:11, 991-1014
CrossRef235
(2004) Rofecoxib, Merck, and the FDA. New England Journal of Medicine 351:27, 2875-2878
Full Text236
Bèr Pleumeekers. (2004) COX-2-remmers: in dubio abstine. Huisarts en Wetenschap 47:13, 15-16
CrossRef237
Chengsheng Liu, Kashappa Goud H. Desai, Chenguang Liu, Hyun J. Park. (2004) Enhancement of dissolution rate of rofecoxib using solid dispersions with urea. Drug Development Research 63:4, 181-189
CrossRef
- Letters
